[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100513622":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":37,"responsibleParty":74,"collaborators":78,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":20,"eligibilityCriteria":86,"healthyVolunteers":83,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":20,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":20,"overallStatus":39,"whyStopped":20,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"McMaster Children's Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Fecal Microbiota Transpant","EXPERIMENTAL","Participants will receive a Fecal Microbiota transplant Infusion via participants' existing enteral feeding tubes or via elective upper endoscopy (with infusion into the duodenum). Most patients with SBS at MCH and HSC have an existing enteral feeding tube (gastrostomy or jejunostomy tube).",[13],"Biological: Fecal Microbiota Transplant",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","Fecal Microbiota Transplant","Participants will receive approximately 50 grams of human stool\u002F150mL (approximately 107 microbes\u002FmL of suspension) in saline, prepared as per standard collection, preparation, and screening protocols for FMT infusion developed by our institutional stool bank in accordance with recognized standards. Fecal microbiota transplant infused via existing enteral feeding tube or upper elective endoscopy (with infusion into the duodenum) x1.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Nikhil Pai, MD","McMaster Children's Hospital (McMater University)","PRINCIPAL_INVESTIGATOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Fariha Chowdhury, BASc, MSc, PhD(c)","CONTACT","647-787-8297","chowdf1@mcmaster.ca",{"name":33,"role":29,"phone":34,"phoneExt":35,"email":36},"Nikhil Pai, BSc, MD, CNSC, FRCPC, FAAP","905-521-2100","73587","pain@mcmaster.ca",[38,55],{"facility":5,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Hamilton","Ontario","L8N 3Z5","Canada","CA",{"type":46,"coordinates":47},"Point",[48,49],-79.84963,43.25011,{"lat":49,"lon":48},[52,54],{"name":23,"role":29,"phone":34,"phoneExt":35,"email":53},"pailab@mcmaster.ca",{"name":28,"role":29,"phone":20,"phoneExt":20,"email":20},{"facility":56,"status":57,"city":58,"state":41,"zip":59,"country":43,"countryCode":44,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Hospital for Sick Children (SickKids)","NOT_YET_RECRUITING","Toronto","M5G 1X8",{"type":46,"coordinates":61},[62,63],-79.39864,43.70643,{"lat":63,"lon":62},[66,70,73],{"name":67,"role":29,"phone":68,"phoneExt":20,"email":69},"Varsha Lillman, BSc","416-813-1500","varsha.lilman@sickkids.ca",{"name":71,"role":29,"phone":68,"phoneExt":20,"email":72},"Yaron Avitzur, MD","yaron.avitzur@sickkids.ca",{"name":71,"role":25,"phone":20,"phoneExt":20,"email":20},{"type":25,"investigatorFullName":75,"investigatorTitle":76,"investigatorAffiliation":77,"oldNameTitle":20,"oldOrganization":20},"Nikhil Pai","Associate Professor, Division of Pediatric Gastroenterology & Nutrition","Hamilton Health Sciences Corporation",[79],{"name":80,"class":6},"The Hospital for Sick Children","100513622","phase-1-pilot-feasibility-study-of-fecal-microbiota-transplant-for-the-treatment-of-small-intestinal-bacterial-overgrowth-100513622",false,"NCT05967871","Pilot Feasibility Study of Fecal Microbiota Transplant for the Treatment of Small Intestinal Bacterial Overgrowth","Inclusion Criteria:\n\n* Patients 3-18 years old\n* Patients will discontinue antibiotics for at least 1 week prior to FMT\n* A diagnosis of SIBO established through lactose breath test (LBT), and showing of symptoms of SIBO\n\nExclusion Criteria:\n\n* Participants will not be permitted to start any new treatments (including antibiotics, probiotics, antacid treatments, or antimotility treatments) until Week 8, unless clinically indicated\n* We will exclude participants \\\u003C3yo to avoid potential concerns of microbial transmission in young children, and to ensure participants are developmentally able to perform LBT\n\n  * All potential participants should request a referral through their primary, or subspecialty physician. We would be pleased to help facilitate this contact if needed, provided the appropriate contact information can be sent.","ALL","3 Years","18 Years",{"count":91,"type":92},20,"ESTIMATED","INTERVENTIONAL",[95],"PHASE1","The objective of the study is to assess feasibility, and clinical efficacy of a novel Fecal Microbiota Transplantation protocol for the treatment of pediatric small intestinal bacterial overgrowth (SIBO).",[98],"Small Intestinal Bacterial Overgrowth","2025-08-15",{"date":101,"type":102},"2025-08-21","ACTUAL",{"date":104,"type":102},"2024-03-11",{"date":106,"type":92},"2026-12-31",{"name":5,"class":6},2]